Similar articles

• Analysis of risk factors for recurrence of hepatocellular carcinoma after orthotopic liver transplantation.

  Lohmann R, Bechstein WO, Langrehr JM, Knoop M, Lobeck H, Keck H, Lemmems HP, Blumhardt G, Neuhaus P. Lohmann R, et al. Transplant Proc. 1995 Feb;27(1):1245-6. Transplant Proc. 1995. PMID: 7533376 Clinical Trial. No abstract available.
• A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma.

  Söderdahl G, Bäckman L, Isoniemi H, Cahlin C, Höckerstedt K, Broomé U, Mäkisalo H, Friman S, Ericzon BG. Söderdahl G, et al. Transpl Int. 2006 Apr;19(4):288-94. doi: 10.1111/j.1432-2277.2006.00279.x. Transpl Int. 2006. PMID: 16573544 Clinical Trial.
• [Adjuvant chemotherapy after orthotopic liver transplantation for advanced hepatocellular carcinoma].

  Zhang ZH, Ma LW, Song SB, Xiu DR, Wang JJ, Yang XX, Jia YM. Zhang ZH, et al. Zhonghua Zhong Liu Za Zhi. 2005 Jan;27(1):45-7. Zhonghua Zhong Liu Za Zhi. 2005. PMID: 15771799 Chinese.
• How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?

  Schwartz M, Roayaie S, Llovet J. Schwartz M, et al. J Hepatol. 2005 Oct;43(4):584-9. doi: 10.1016/j.jhep.2005.07.019. J Hepatol. 2005. PMID: 16120468 Review. No abstract available.
• Surgery and transplantation for hepatocellular cancer.

  Wall WJ, Marotta PJ. Wall WJ, et al. Liver Transpl. 2000 Nov;6(6 Suppl 2):S16-22. doi: 10.1053/jlts.2000.19010. Liver Transpl. 2000. PMID: 11084080 Review.